These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 34295963)
1. Improving STING Agonist Delivery for Cancer Immunotherapy Using Biodegradable Mesoporous Silica Nanoparticles. Park KS; Xu C; Sun X; Louttit C; Moon JJ Adv Ther (Weinh); 2020 Oct; 3(10):. PubMed ID: 34295963 [TBL] [Abstract][Full Text] [Related]
2. Positron Emission Tomography-Guided Photodynamic Therapy with Biodegradable Mesoporous Silica Nanoparticles for Personalized Cancer Immunotherapy. Xu C; Nam J; Hong H; Xu Y; Moon JJ ACS Nano; 2019 Oct; 13(10):12148-12161. PubMed ID: 31556987 [TBL] [Abstract][Full Text] [Related]
3. Nanoparticle-Mediated STING Agonist Delivery for Enhanced Cancer Immunotherapy. Zhou Q; Zhou Y; Li T; Ge Z Macromol Biosci; 2021 Aug; 21(8):e2100133. PubMed ID: 34117839 [TBL] [Abstract][Full Text] [Related]
4. Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases. Zhou S; Cheng F; Zhang Y; Su T; Zhu G Acc Chem Res; 2023 Nov; 56(21):2933-2943. PubMed ID: 37802125 [TBL] [Abstract][Full Text] [Related]
5. Targeted Delivery of STING Agonist via Albumin Nanoreactor Boosts Immunotherapeutic Efficacy against Aggressive Cancers. Miao Z; Song X; Xu A; Yao C; Li P; Li Y; Yang T; Shen G Pharmaceutics; 2024 Sep; 16(9):. PubMed ID: 39339252 [No Abstract] [Full Text] [Related]
6. The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy. Hines JB; Kacew AJ; Sweis RF Curr Oncol Rep; 2023 Mar; 25(3):189-199. PubMed ID: 36705879 [TBL] [Abstract][Full Text] [Related]
8. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy. Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological Activation of cGAS for Cancer Immunotherapy. Garland KM; Rosch JC; Carson CS; Wang-Bishop L; Hanna A; Sevimli S; Van Kaer C; Balko JM; Ascano M; Wilson JT Front Immunol; 2021; 12():753472. PubMed ID: 34899704 [TBL] [Abstract][Full Text] [Related]
10. Impact of in vivo fate of STING agonist-loaded lipid nanoparticles on antitumor immunity. Endo R; Ueda T; Nagaoki T; Shima N; Sato Y; Harashima H; Nakamura T J Control Release; 2024 Aug; 372():609-618. PubMed ID: 38942082 [TBL] [Abstract][Full Text] [Related]
11. Supramolecular Cyclic Dinucleotide Nanoparticles for STING-Mediated Cancer Immunotherapy. Xu L; Deng H; Wu L; Wang D; Shi L; Qian Q; Huang X; Zhu L; Gao X; Yang J; Su Y; Feng J; Zhu X ACS Nano; 2023 Jun; 17(11):10090-10103. PubMed ID: 37253192 [TBL] [Abstract][Full Text] [Related]
12. Oxidation-Responsive PolyMOF Nanoparticles for Combination Photodynamic-Immunotherapy with Enhanced STING Activation. Zhou Q; Dutta D; Cao Y; Ge Z ACS Nano; 2023 May; 17(10):9374-9387. PubMed ID: 37141569 [TBL] [Abstract][Full Text] [Related]
13. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration. Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789 [TBL] [Abstract][Full Text] [Related]
14. Nanomedicinal delivery of stimulator of interferon genes agonists: recent advances in virus vaccination. Chattopadhyay S; Hu CJ Nanomedicine (Lond); 2020 Dec; 15(29):2883-2894. PubMed ID: 33252301 [TBL] [Abstract][Full Text] [Related]
15. Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy. Chen X; Xu Z; Li T; Thakur A; Wen Y; Zhang K; Liu Y; Liang Q; Liu W; Qin JJ; Yan Y Biomark Res; 2024 Jan; 12(1):2. PubMed ID: 38185685 [TBL] [Abstract][Full Text] [Related]
16. Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives. Huang C; Shao N; Huang Y; Chen J; Wang D; Hu G; Zhang H; Luo L; Xiao Z Mater Today Bio; 2023 Dec; 23():100839. PubMed ID: 38024837 [TBL] [Abstract][Full Text] [Related]
17. Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy. Wilson J; Kimmel B; Arora K; Chada N; Bharti V; Kwiatkowski A; Finklestein J; Hanna A; Arner E; Sheehy T; Pastora L; Yang J; Pagendarm H; Stone P; Taylor B; Hubert L; Gibson-Corley K; May J; McLean J; Rathmell J; Richmond A; Rathmell W; Balko J; Fingleton B; Hargrove-Wiley E Res Sq; 2024 May; ():. PubMed ID: 38766114 [TBL] [Abstract][Full Text] [Related]
18. Unlocking the promise of systemic STING agonist for cancer immunotherapy. Sun X; Zhou X; Lei YL; Moon JJ J Control Release; 2023 May; 357():417-421. PubMed ID: 37001564 [TBL] [Abstract][Full Text] [Related]
19. STING agonist-loaded mesoporous manganese-silica nanoparticles for vaccine applications. Xu C; Dobson HE; Yu M; Gong W; Sun X; Park KS; Kennedy A; Zhou X; Xu J; Xu Y; Tai AW; Lei YL; Moon JJ J Control Release; 2023 May; 357():84-93. PubMed ID: 36948420 [TBL] [Abstract][Full Text] [Related]
20. Lipid-based nanoparticles as drug delivery systems for cancer immunotherapy. Hao Y; Ji Z; Zhou H; Wu D; Gu Z; Wang D; Ten Dijke P MedComm (2020); 2023 Aug; 4(4):e339. PubMed ID: 37560754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]